Etiopathogenic Role of Surfactant Protein D (SP-D) in the Clinical and Immunological Expression of Primary Sjögren Syndrome (pSS). High SP-D levels were found with severe glandular involvement, hypergammaglobulinemia, leukopenia, extraglandular manifestations, and positive anti-Ro/La antibodies. PubMed, J Rheumatol, 2014 Nov 1. (Also see Sjogren's Research: Antibodies)
Prevalence of distal renal tubular acidosis in primary Sjögren's syndrome (pSS). Furosemide and fludrocortisone (FF) cannot replace NH4Cl in testing urinary acidification in pSS, but may be considered as a screening tool. PubMed, Rheumatology (Oxford), 2014 Oct 29. (Also see Diagnosis of Sjögren's Syndrome)
Prevalence of and factors associated with increased arterial stiffness in patients with primary Sjögren's syndrome (pSS). Women with pSS had higher pulse wave velocity (PWV) than controls. PubMed, Arthritis Care Res (Hoboken), 2014 Oct 9. (Also see Symptoms and Complications of Sjögren's Syndrome)
Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis (PM) and dermatomyositis (DM). A 12-week supervised low-intensity resistance training program associated with partial blood flow restriction may be safe and effective in improving muscle strength and function as well as muscle mass and health-related quality of life in patients with PM and DM. Arthritis Research & Therapy, 25 October 2014. (Also see Treatments for Dermatomyositis and Polymyositis)
Cutaneous ulceration in dermatomyositis (DM): Association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease (ILD). There was a strong association between anti-MDA5 antibodies and cutaneous ulcers, with the novel finding that the association of cutaneous ulcers with ILD depends upon the presence of anti-MDA5 antibodies. PubMed, Arthritis Care Res (Hoboken), 2014 Oct 20. (Also see Diagnosis of Dermatomyositis?)
New treatments for inflammatory rheumatic disease. This article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules. PubMed, Immunol Res, 2014 Nov 9. (Also see Biologic Agents)
Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? A summary of current data on low-dose MTX-associated toxicity, its prevention and predictors, keeping in mind practical RA clinical care. PubMed, Immunol Res, 2014 Nov 13. (Also see Medications for Rheumatoid Arthritis and Methotrexate)
Indirect Comparison Between Subcutaneous Biologic Agents in Ankylosing Spondylitis (AS). Golimumab, compared to placebo, may be the drug that provides the highest probability of achieving ASAS20 response in AS patients naive to biologic treatments at 12 weeks. PubMed, Clin Drug Investig, 2014 Nov 12. (Also see Biologic Agents)
Thoracic Manifestations of Connective Tissue Diseases. The most important thoracic manifestations of CTDs are interstitial lung disease and pulmonary arterial hypertension, with nonspecific interstitial pneumonia being the most common pattern of interstitial lung disease. PubMed, Curr Probl Diagn Radiol, 2014 Aug 14. (Also see Connective Tissue Disease)
Risk factors of systemic lupus erythematosus (SLE) flares during pregnancy. The SLE flares during pregnancy make the difference between an uncomplicated pregnancy and pregnancy with maternal and fetal complications. Knowledge of risk factors leads the best treatment strategies to reduce flares and fetal complications in SLE patients. PubMed, Immunol Res, 2014 Nov 13. (Also see Symptoms and Complications of Lupus)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: